January Top 10: Furiex


In the following video, Motley Fool health-care analyst David Williamson continues his look at the top-performing health-care stocks of last month. Here, he examines Furiex , up a whopping 67% for January, most of which was made in a single day. Three important FDA approvals for type 2 diabetes drugs were granted to the Japanese drugmaker Takeda this past month, with Furiex set to receive a $25 million milestone payment from the drugs, as well as sales royalties and further potential milestone payments, which fueled investor enthusiasm over the company this past month. David tells us some of the history of Furiex, and what investors should be watching for in its pipeline.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article January Top 10: Furiex originally appeared on Fool.com.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.